Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 1238-1245

  McPhail, Lesley D ^a,b   Griffiths, John R ^b   Robinson, Simon P ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CA4P; DMXAA; MRI; VDA; ZD6126

Indexed keywords

CA4P; DMXAA; VDA; ZD6126;

ACETIC ACID; BIOASSAY; BIOMARKERS; DRUG THERAPY; MAGNETIC RESONANCE IMAGING; PHOSPHATES;

TUMORS;

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ASA 1404; BIOLOGICAL MARKER; COMBRETASTATIN A4 PHOSPHATE; DEOXYHEMOGLOBIN; HOE 33342; N ACETYLCOLCHINOL PHOSPHATE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BLOOD VOLUME; COLLAPSE; CONTROLLED STUDY; DRUG MONITORING; FEMALE; FLUORESCENCE MICROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PRIORITY JOURNAL; PROLACTINOMA; RAT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TISSUE OXYGENATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLOOD FLOW; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; HEMOGLOBINS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED WF; STILBENES; TUMOR MARKERS, BIOLOGICAL; XANTHONES;

EID: 35448952260     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.08.025     Document Type: Article

References (37)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 46 (1986) 147-173
2. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49 (1989) 6449-6465
3. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
4. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
5. Siemann D.W., Bibby M.C., Dark G.G., et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11 (2005) 416-420
6. Kelland L.R. Targeting established tumor vasculature: A novel approach to cancer treatment. Curr Cancer Ther Rev 1 (2005) 1-9
7. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumor blood vessels. Nat Rev Cancer 5 (2005) 423-435
8. Michaelis L.C., and Ratain M.J. Measuring response in a post-RECIST world: From black and white to shades of grey. Nat Rev Cancer 6 (2006) 409-414
9. Galbraith S.M., Rustin G.J., Lodge M.A., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20 (2002) 3826-3840
10. Maxwell R.J., Wilson J., Prise V.E., et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumors by dynamic contrast enhanced MRI. NMR Biomed 15 (2002) 89-98
11. Dowlati A., Robertson K., Cooney M., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62 (2002) 3408-3416
12. Robinson S.P., McIntyre D.J., Checkley D., et al. Tumor dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88 (2003) 1592-1597
13. Stevenson J.P., Rosen M., Sun W., et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21 (2003) 4428-4438
14. Galbraith S.M., Maxwell R.J., Lodge M.A., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
15. Evelhoch J.L., LoRusso P.M., He Z., et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10 (2004) 3650-3657
16. McPhail L.M., McIntyre D.J.O., Ludwig C., et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8 (2006) 199-206
17. Padhani A.R., and Choyke P.L. New techniques in oncologic imaging (2006), Taylor and Francis, New York p. 257-269
18. Robinson S.P., Kalber T.L., Howe F.A., et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 7 (2005) 466-474
19. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8 (2002) 1974-1983
20. Galbraith S.M., Chaplin D.J., Lee F., et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 21 (2001) 93-102
21. Workman P., Twentyman P., Balkwill F., et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77 (1998) 1-10
22. Howe F.A., Robinson S.P., Rodrigues L.M., et al. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging 17 (1999) 1307-1318
23. * and arterial blood gases. Magn Reson Imaging 19 (2001) 161-166
24. Denekamp J., Hill S.A., and Hobson B. Vascular occlusion and tumor cell death. Eur J Cancer Clin Oncol 19 (1983) 271-275
25. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 92 (2005) 1599-1610
26. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
27. McKeage M., Fong P., Jeffery M., et al. 5,6-dimethyxanthenone-4-acetic acid in the treatment of refactory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res 12 (2006) 1776-1784
28. O'Connor J.P.B., Jackson A., Parker G.J.M., et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96 (2007) 189-195
29. Murata R., Overgaard J., and Horsman M.R. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumor and normal tissues. Int J Radiat Biol 77 (2001) 195-204
30. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59 (1999) 1626-1634
31. Ferrero E., Villa A., Ferrero M.E., et al. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 56 (1996) 3211-3215
32. Hofmann S., Grasberger H., Jung P., et al. The tumor necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Eur J Med Res 7 (2002) 171-176
33. Lejeune F.J. Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110 (2002) 433-435
34. Nwariaku F.E., Chang J., Zhu X., et al. The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability. Shock 18 (2002) 82-85
35. Kerkar S., Williams M., Blocksom J., et al. TNF-alpha and IL-1beta increase pericyte/endothelial cell co-culture permeability. J Surg Res 132 (2006) 40-45
36. Griffiths J.R., Taylor N.J., Howe F.A., et al. The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys 39 (1997) 697-701
37. Padhani A.R. MRI for evaluating antivascular cancer treatments. Br J Radiol 76 (2003) S60-S80